Trading was light with 725K shares changing hands by the end of trading on Tuesday. Trading volume was down 87.20% under the stocks average daily volume.
Investors are feeling more bullish on shares of Infinity Pharmaceuticals, Inc. lately at least if you consider the downtick in short interest. The company experienced a fall in short interest of -8.81% as of October 13, 2017 from the last reporting period. Short shares decreased 72,014 over that period. Days to cover decreased -1.0 to 0.0 and the percentage of shorted shares was 0.01% on October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (INFI). Meeder Asset Management Inc augmented its holdings by buying 1,448 shares an increase of 121.7% in the quarter. Meeder Asset Management Inc currently owns 2,638 shares with a value of $4,000. The total value of its holdings increased 100.0%. As of quarter end Nationwide Fund Advisors had sold a total of 16,338 shares trimming its position 24.8%. The value of the company’s investment in Infinity Pharmaceuticals, Inc. went from $103,000 to $66,000 a change of $37,000 for the reporting period.
As of the end of the quarter Aperio Group, LLC had disposed of 15,235 shares trimming its stake by 57.7%. The value of the investment in INFI decreased from $41,000 to $15,000 a change of 63.4% quarter to quarter. Simplex Trading, LLC grew its position by buying 6,752 shares an increase of 112,533.3% from 06/30/2017 to 09/30/2017. Simplex Trading, LLC owns 6,758 shares valued at $8,000. The value of the position overall is up by inf%.
In the market the company is trading up by 0.43% percent from yesterday’s close. The stock last traded at $2.33 significantly above the 50 day moving average which is $1.75 and impressively higher than the 200 day moving average of $1.61. The 50 day moving average was up $0.58 whereas the 200 day average was up by +44.71%.
In the latest earnings report the EPS was $-1.39 and is estimated to be $-0.92 for the current year with 50,689,000 shares outstanding. Analysts expect next quarter’s EPS will be $-0.20 and the next full year EPS is anticipated to be $-1.50.
Infinity Pharmaceuticals, Inc., launched on May 11, 2000, is a biopharmaceutical company. The Company is involved in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology..